

## Prior Authorization Request Form Insulin – Long & Short acting

Standard  Urgent

Reconsideration/Appeal

### Patient Information

Patient Name: \_\_\_\_\_ DOB (mm/dd/yyyy): \_\_\_\_\_ Gender: \_\_\_\_\_  
 Address: \_\_\_\_\_ City: \_\_\_\_\_ State & Zip: \_\_\_\_\_  
 Cardholder ID: \_\_\_\_\_ Group #: \_\_\_\_\_ Relationship Code: \_\_\_\_\_  
 Phone Number: \_\_\_\_\_ Email address: \_\_\_\_\_

### Prescriber Information

Prescriber Name: \_\_\_\_\_ Specialty: \_\_\_\_\_ NPI: \_\_\_\_\_  
 Address: \_\_\_\_\_ City: \_\_\_\_\_ State & Zip: \_\_\_\_\_  
 Office Contact: \_\_\_\_\_ Phone Number: \_\_\_\_\_ Fax Number: \_\_\_\_\_

### Medication Information

Drug Name: \_\_\_\_\_ Strength: \_\_\_\_\_ Quantity: \_\_\_\_\_  
 Directions: \_\_\_\_\_ Day Supply: \_\_\_\_\_  
 Indicate Request Type:  New Start  Renewal      Therapy Start Date (if applicable): \_\_\_\_\_  
 Diagnosis: \_\_\_\_\_ ICD 10 Code: \_\_\_\_\_

### Prior Authorization Request Information

**\*\*Supporting documentation (i.e., chart notes, labs, etc.) must be attached to avoid processing delays\*\***

**Please be aware that our preferred insulins are insulin lispro, insulin aspart, insulin glargine, insulin glargine-yfgn, and insulin degludec. Any brand name insulin will require an inadequate clinical response with one of the following generic products of similar duration of action (for example: Humalog/Novolog require an inadequate clinical response with insulin aspart or insulin lispro).**

For all requests:

1. Does the patient have any FDA contraindications to the requested agent?  Yes  No
2. Will the patient be taking any other medications in combination with the requested agent for the treatment of this diagnosis? If yes, please list: \_\_\_\_\_  Yes  No
3. Has the patient had an inadequate clinical response of at least 12 weeks, intolerance, or contraindication to any medications used to treat this diagnosis? If yes, please list below.  Yes  No

Drug Name/Strength:	Start Date:	End Date:	Outcome:

Please continue to the next page.

Patient Name:	DOB:
---------------	------

**For Renewal Requests:**

1. Has the patient had a positive clinical response to therapy? Must submit objective documentation.  Yes  No

2. Does the patient have any FDA contraindications to the requested agent?  Yes  No

Prescriber Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Authorized Agent's Name: \_\_\_\_\_

**Please fax this request to 602-585-0588 or our secure email at [care@disclosedrx.com](mailto:care@disclosedrx.com)**  
**Mail Requests to: DisclosedRx Clinical Team**  
**PO Box 701 Washington, IN 47501**

**Additional Comments/Notes:**